KTTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KTTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Pasithea Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0. Pasithea Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2025-03-15), Pasithea Therapeutics's share price is $1.11. Pasithea Therapeutics's Median PS Value is $0.00. Therefore, Pasithea Therapeutics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Pasithea Therapeutics's Median PS Value or its related term are showing as below:
The historical data trend for Pasithea Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pasithea Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Median PS Value | - | - | - | - |
Pasithea Therapeutics Quarterly Data | |||||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Pasithea Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Pasithea Therapeutics's Price-to-Median-PS-Value falls into.
Pasithea Therapeutics's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0 | * | ||
= | 0.00 |
10-Year Median PS Ratio is .
Pasithea Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pasithea Therapeutics (NAS:KTTA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Pasithea Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 1.11 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Pasithea Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Graeme Martin Currie | officer: Chief Development Officer | 51 BARBAREE WAY, TIBURON CA 94920 |
Lawrence Steinman | director | 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121 |
Bradford Manning | 10 percent owner | C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902 |
Paul B Manning | 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Tiger Lily Capital, Llc | 10 percent owner | C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902 |
Pd Joint Holdings, Llc Series 2016-a | 10 percent owner | C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902 |
Elderhill Corp | other: Member of 10% owner group | C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5 |
Concord Ip2 Ltd. | other: Member of 10% owner group | C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5 |
David Delaney | other: Member of 10% owner group | C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5 |
Eric Shahinian | other: Member of 10% owner group | 350 PARK AVE, 13TH FL, NEW YORK NY 10022 |
Alfred J Novak | director | 325 NE 6TH ST, BOCA RATON FL 33432 |
Camac Partners, Llc | other: Member of 10% owner group | 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022 |
Camac Capital, Llc | other: Member of 10% owner group | 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022 |
Camac Fund, Lp | other: Member of 10% owner group | CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022 |
Leonite Capital Llc | other: Member of 10% owner group | 1 HILLCREST CENTER DR., SUITE 232, SPRING VALLEY NY 10977 |
From GuruFocus
By GlobeNewswire • 12-19-2023
By sperokesalga sperokesalga • 02-23-2023
By sperokesalga sperokesalga • 03-02-2023
By Marketwired • 09-26-2024
By Marketwired • 06-13-2024
By Marketwired • 04-29-2024
By Marketwired • 06-30-2023
By Marketwired • 08-28-2024
By sperokesalga sperokesalga • 05-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.